https://www.selleckchem.com/pr....oducts/sar439859.htm
The PEGASUS-TIMI 54 trial inclusion criteria effectively identified high-risk patients with recent myocardial infarction (MI) who would benefit from continuing dual antiplatelet therapy (DAPT) with ticagrelor for more than 12months. It is unknown how many real-world patients meet these criteria during the acute phase of ST-elevation MI (STEMI), or the extent to which these criteria predict a patient's risk and prognosis. Study objectives were (1) determine the proportion of PEGASUS-TIMI 54-like patients (PG-l) in a real-world cohort o
Like
Comment
Share
